Brokers Issue Forecasts for HRMY FY2025 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Harmony Biosciences in a research note issued on Tuesday, May 13th. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will post earnings per share of $2.68 for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.19. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm had revenue of $184.73 million during the quarter, compared to analyst estimates of $184.26 million. During the same quarter last year, the business earned $0.67 EPS. The company’s revenue was up 19.5% compared to the same quarter last year.

HRMY has been the subject of several other research reports. Deutsche Bank Aktiengesellschaft began coverage on shares of Harmony Biosciences in a report on Tuesday, February 11th. They set a “buy” rating and a $55.00 price target for the company. UBS Group reduced their price objective on shares of Harmony Biosciences from $55.00 to $48.00 and set a “buy” rating for the company in a research report on Monday, April 28th. Mizuho raised their price objective on shares of Harmony Biosciences from $44.00 to $48.00 and gave the stock an “outperform” rating in a research report on Thursday. Needham & Company LLC reaffirmed a “buy” rating and set a $49.00 price objective on shares of Harmony Biosciences in a research report on Tuesday, May 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of Harmony Biosciences in a research report on Tuesday, April 8th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Harmony Biosciences has an average rating of “Buy” and an average price target of $52.78.

Harmony Biosciences Stock Up 2.5%

Harmony Biosciences stock opened at $35.07 on Thursday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. Harmony Biosciences has a 52-week low of $26.47 and a 52-week high of $41.61. The firm has a 50 day moving average price of $31.45 and a two-hundred day moving average price of $33.96. The firm has a market cap of $2.01 billion, a price-to-earnings ratio of 16.62, a PEG ratio of 0.47 and a beta of 0.82.

Institutional Trading of Harmony Biosciences

Several hedge funds have recently bought and sold shares of the business. Hillsdale Investment Management Inc. grew its position in Harmony Biosciences by 0.4% in the 4th quarter. Hillsdale Investment Management Inc. now owns 68,000 shares of the company’s stock valued at $2,340,000 after purchasing an additional 300 shares during the period. Aurora Investment Counsel grew its position in Harmony Biosciences by 0.6% in the 1st quarter. Aurora Investment Counsel now owns 61,667 shares of the company’s stock valued at $2,047,000 after purchasing an additional 374 shares during the period. O Shaughnessy Asset Management LLC grew its position in Harmony Biosciences by 2.1% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 20,450 shares of the company’s stock valued at $704,000 after purchasing an additional 420 shares during the period. GAMMA Investing LLC grew its position in Harmony Biosciences by 92.6% in the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after purchasing an additional 436 shares during the period. Finally, Rhumbline Advisers grew its position in Harmony Biosciences by 0.4% in the 1st quarter. Rhumbline Advisers now owns 109,073 shares of the company’s stock valued at $3,620,000 after purchasing an additional 485 shares during the period. Institutional investors and hedge funds own 86.23% of the company’s stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.